AIDS
MCID: HMN044
MIFTS: 75

Human Immunodeficiency Virus Type 1 (AIDS)

Categories: Cancer diseases, Genetic diseases, Immune diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Human Immunodeficiency Virus Type 1

MalaCards integrated aliases for Human Immunodeficiency Virus Type 1:

Name: Human Immunodeficiency Virus Type 1 57 36 75
Aids 57 75 53 2 16
Aids, Delayed/rapid Progression to 57 12 5
Hiv/aids 57 41 2
Hiv-1 Viremia, Susceptibility to 57 5
Hiv-1, Susceptibility to 57 5
Human Immunodeficiency Virus Type 1, Susceptibility to 57
Rapid Progression to Aids from Hiv1 Infection 57
Human Immunodeficiency Virus I Infection 71
Hiv-1 Disease, Delayed Progression of 57
Hiv-1 Disease, Rapid Progression of 57
Acquired Immunodeficiency Syndrome 71
Hiv1 Infection, Resistance to 57
Hiv Type 1, Susceptibility to 57
Hiv Infection, Resistance to 57
Hiv/aids, Susceptibility to 57
Aids, Rapid Progression to 57
Aids, Slow Progression to 57
Hiv-1, Resistance to 57
Aids, Resistance to 57
Hiv1, Resistance to 57
Hiv-Infection/aids 71
Hiv-1 Infection 16
Hiv1 Infection 57
Hiv-1 Viremia 57
Hiv Type 1 57
Hiv-1 57
Hiv1 57

Classifications:



External Ids:

OMIM® 57 609423
UMLS 71 C0001175 C0276500 C0497169

Summaries for Human Immunodeficiency Virus Type 1

MedlinePlus: 41 What is HIV? HIV stands for human immunodeficiency virus. It harms your immune system by destroying a type of white blood cell that helps your body fight infection. This puts you at risk for serious infections and certain cancers. What is AIDS? AIDS stands for acquired immunodeficiency syndrome. It is the final stage of infection with HIV. It happens when the body's immune system is badly damaged because of the virus. Not everyone with HIV develops AIDS. How does HIV spread? HIV can spread in different ways: Through unprotected sex with a person with HIV. This is the most common way that it spreads. By sharing drug needles. Through contact with the blood of a person with HIV. From mother to baby during pregnancy, childbirth, or breastfeeding. Who is at risk for HIV infection? Anyone can get HIV, but certain groups have a higher risk of getting it: People who have another sexually transmitted disease (STD). Having an STD can increase your risk of getting or spreading HIV. People who inject drugs with shared needles. Gay and bisexual men. Black/African Americans and Hispanic/Latino Americans. They make up a higher proportion of new HIV diagnoses and people with HIV, compared to other races and ethnicities. People who engage in risky sexual behaviors, such as not using condoms. Factors such as stigma, discrimination, income, education, and geographic region can also affect people's risk for HIV. What are the symptoms of HIV/AIDS? The first signs of HIV infection may be flu-like symptoms: Fever Chills Rash Night sweats Muscle aches Sore throat Fatigue Swollen lymph nodes Mouth ulcers These symptoms may come and go within two to four weeks. This stage is called acute HIV infection. If the infection is not treated, it becomes chronic HIV infection. Often, there are no symptoms during this stage. If it is not treated, eventually the virus will weaken your body's immune system. Then the infection will progress to AIDS. This is the late stage of HIV infection. With AIDS, your immune system is badly damaged. You can get more and more severe infections. These are known as opportunistic infections (OIs). Some people may not feel sick during the earlier stages of HIV infection. So the only way to know for sure whether you have HIV is to get tested. How do I know if I have HIV? A blood test can tell if you have HIV infection. Your health care provider can do the test, or you can use a home testing kit. You can also use the CDC Testing Locator to find free testing sites. What are the treatments for HIV/AIDS? There is no cure for HIV infection, but it can be treated with medicines. This is called antiretroviral therapy (ART). ART can make HIV infection a manageable chronic condition. It also reduces the risk of spreading the virus to others. Most people with HIV live long and healthy lives if they get and stay on ART. It's also important to take care of yourself. Making sure that you have the support you need, living a healthy lifestyle, and getting regular medical care can help you enjoy a better quality of life. Can HIV/AIDS be prevented? You can reduce the risk of spreading HIV by: Getting tested for HIV. Choosing less risky sexual behaviors. This includes limiting the number of sexual partners you have and using latex condoms every time you have sex. If your or your partner is allergic to latex, you can use polyurethane condoms. Getting tested and treated for sexually transmitted diseases (STDs). Not injecting drugs. Talking to your health care provider about medicines to prevent HIV: PrEP (pre-exposure prophylaxis) is for people who don't already have HIV but are at very high risk of getting it. PrEP is daily medicine that can reduce this risk. PEP (post-exposure prophylaxis) is for people who have possibly been exposed to HIV. It is only for emergency situations. PEP must be started within 72 hours after a possible exposure to HIV. NIH: National Institutes of Health

MalaCards based summary: Human Immunodeficiency Virus Type 1, also known as aids, is related to immune deficiency disease and acquired immunodeficiency syndrome, and has symptoms including fever and pruritus. An important gene associated with Human Immunodeficiency Virus Type 1 is KIR3DL1 (Killer Cell Immunoglobulin Like Receptor, Three Ig Domains And Long Cytoplasmic Tail 1), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Mycophenolic acid and Cytarabine have been mentioned in the context of this disorder. Affiliated tissues include t cells, brain and lymph node, and related phenotypes are nervous system and homeostasis/metabolism

CDC: 2 HIV is a virus spread through certain body fluids that attacks the body's immune system, specifically the CD4 cells, often called T cells. Over time, HIV can destroy so many of these cells that the body can't fight off infections and disease. These special cells help the immune system fight off infections. Untreated, HIV reduces the number of CD4 cells (T cells) in the body. This damage to the immune system makes it harder and harder for the body to fight off infections and some other diseases. Opportunistic infections or cancers take advantage of a very weak immune system and signal that the person has AIDS. Learn more about the stages of HIV and how to know whether you have HIV.

OMIM®: 57 The pathogenesis of HIV infection and the progression from infection to AIDS vary significantly between exposed individuals. Infection occurs after the virus, which has macrophage (M)- and T lymphocyte (T)-tropic strains and more than 12 subtypes, survives an array of nonspecific, nongenetic environmental and host factors. (609423) (Updated 08-Dec-2022)

Wikipedia: 75 Human immunodeficiency virus infection and acquired immunodeficiency syndrome (HIV/AIDS) is a spectrum... more...

Related Diseases for Human Immunodeficiency Virus Type 1

Diseases related to Human Immunodeficiency Virus Type 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2624)
# Related Disease Score Top Affiliating Genes
1 immune deficiency disease 32.9 IL10 IFNG CXCR4 CXCL12 CX3CR1 CD209
2 acquired immunodeficiency syndrome 32.6 IL10 IFNG CCR5 CCR2 CCL3
3 severe combined immunodeficiency 32.1 IL4R IL10 IFNG CXCR4 CXCL12
4 intraocular lymphoma 32.0 IL10 CXCR4 CXCL12
5 human immunodeficiency virus infectious disease 31.7 KIR3DL1 IL10 IFNG CXCR4 CXCL12 CX3CR1
6 mycobacterium tuberculosis 1 31.6 IL10 IFNG CXCR4 CD209 CCL3
7 pulmonary tuberculosis 31.6 IL10 IFNG CCL3 CCL2
8 leishmaniasis 31.6 IL10 IFNG CCR5 CCL2
9 aids dementia complex 31.6 CXCR4 CXCL12
10 viral infectious disease 31.6 TLR3 KIR3DL1 IL10 IFNG CXCR4 CD209
11 toxoplasmosis 31.5 IL10 IFNG CCR5 CCL3
12 bacterial vaginosis 31.5 IL10 CCR5 CCL5
13 hepatitis c 31.5 TLR3 IL10 IFNG CD209
14 syphilis 31.5 HLA-C CD209 CCR5
15 pertussis 31.4 CXCR4 CXCL12 CCL5 CCL2 CCL11
16 meningitis 31.3 IL10 IFNG CCL5 CCL3 CCL2
17 pelvic inflammatory disease 31.3 IFNG CXCL12 CCL2
18 trichomoniasis 31.3 IL10 CCR5 CCL5
19 respiratory syncytial virus infectious disease 31.3 CCL5 CCL3
20 chlamydia 31.3 IL10 IFNG CCR5 CCL2
21 peripheral nervous system disease 31.3 IL10 IFNG CXCR4 CXCL12 CCL5 CCL2
22 plasmodium falciparum malaria 31.3 IL10 IFNG CCL5 CCL3
23 demyelinating disease 31.2 IL10 IFNG CCL5 CCL3 CCL2
24 vaginitis 31.2 IL10 CCR5 CCL5
25 cytomegalovirus retinitis 31.2 IL10 IFNG CXCL12 CCR5 CCR2
26 encephalitis 31.2 TLR3 IL10 CXCR4 CD209 CCR5 CCL5
27 autoimmune disease 31.2 IL10 IFNG CCR5 CCL5 CCL3 CCL2
28 schistosomiasis 31.2 IL10 IFNG CCL5 CCL3 CCL2
29 herpes zoster 31.1 TLR3 IL10 IFNG CCR5
30 tropical spastic paraparesis 31.1 IFNG CCL5 CCL3
31 lymphadenitis 31.0 IL10 IFNG CD209
32 allergic disease 31.0 IL4R IL10 IFNG CCL5 CCL3 CCL11
33 genital herpes 30.9 TLR3 CCR5 CCL5
34 periodontitis 30.9 IL10 IFNG CCL2
35 dengue disease 30.9 LOC117307477 IL10 CD209 CCL5 CCL3
36 leprosy 3 30.9 IL10 IFNG HLA-C CD209 CCL2
37 lung disease 30.9 IL10 IFNG CXCR4 CXCR1 CCR5 CCL5
38 bronchopneumonia 30.9 IL10 CCL3 CCL2
39 bacterial pneumonia 30.9 IL10 IFNG CCL3 CCL2
40 gingivitis 30.9 IL10 IFNG CCL5 CCL2
41 chickenpox 30.9 TLR3 IL10 IFNG
42 leptospirosis 30.9 IL10 IFNG CCL2
43 thrombocytopenia 30.9 IL10 IFNG CXCL12 CX3CR1 CD209 CCL2
44 ebola hemorrhagic fever 30.9 TLR3 IL10 CD209 CCR5 CCL3 CCL2
45 hepatitis a 30.8 TLR3 IL10 IFNG CCR5
46 otitis media 30.8 IL10 IFNG CCL5 CCL2 CCL11
47 kidney disease 30.8 IL10 IFNG CXCR4 CCR5 CCL5 CCL2
48 viral encephalitis 30.8 TLR3 IL10 CCL5 CCL2
49 polyradiculoneuropathy 30.8 IL10 IFNG CXCL12 CCL5
50 severe acute respiratory syndrome 30.7 IL10 IFNG HLA-C CD209 CCL5 CCL3

Graphical network of the top 20 diseases related to Human Immunodeficiency Virus Type 1:



Diseases related to Human Immunodeficiency Virus Type 1

Symptoms & Phenotypes for Human Immunodeficiency Virus Type 1

Clinical features from OMIM®:

609423 (Updated 08-Dec-2022)

UMLS symptoms related to Human Immunodeficiency Virus Type 1:


fever; pruritus

MGI Mouse Phenotypes related to Human Immunodeficiency Virus Type 1:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 10.27 CCL2 CCL3 CCL3L1 CCR2 CCR5 CX3CR1
2 homeostasis/metabolism MP:0005376 10.25 CCL2 CCL3 CCL3L1 CCNT1 CCR2 CCR5
3 immune system MP:0005387 10.19 CCL11 CCL2 CCL3 CCL3L1 CCL5 CCNT1
4 digestive/alimentary MP:0005381 10.15 CCL2 CCL3 CCL3L1 CCR2 CCR5 CD209
5 cellular MP:0005384 10.1 CCL2 CCL3 CCL3L1 CCR2 CCR5 CD209
6 muscle MP:0005369 10.03 CCL2 CCR5 CX3CR1 CXCL12 CXCR4 IFNG
7 neoplasm MP:0002006 10.02 CCL2 CCR2 CCR5 CXCR4 IFNG IL10
8 hematopoietic system MP:0005397 9.91 CCL11 CCL2 CCL3 CCL3L1 CCL5 CCNT1
9 respiratory system MP:0005388 9.76 CCL11 CCR2 CCR5 CXCR4 IFNG IL10
10 mortality/aging MP:0010768 9.47 CCL2 CCL3 CCL3L1 CCR2 CCR5 CD209

Drugs & Therapeutics for Human Immunodeficiency Virus Type 1

Drugs for Human Immunodeficiency Virus Type 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 745)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mycophenolic acid Approved, Investigational Phase 4 24280-93-1 446541
2
Cytarabine Approved, Investigational Phase 4 147-94-4 6253
3
Cyclophosphamide Approved, Investigational Phase 4 50-18-0, 6055-19-2 2907
4
Vincristine Approved, Investigational Phase 4 2068-78-2, 57-22-7 5978
5
Rituximab Approved Phase 4 174722-31-7
6
Zidovudine Approved Phase 4 30516-87-1 35370
7
Didanosine Approved Phase 4 69655-05-6 50599
8
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
9
Sertraline Approved Phase 4 79617-96-2 68617
10
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 4112 126941
11
Zalcitabine Approved, Investigational Phase 4 7481-89-2 24066
12
Levoleucovorin Approved, Experimental, Investigational Phase 4 68538-85-2, 58-05-9, 73951-54-9 149436 6006
13
Bleomycin Approved, Investigational Phase 4 9041-93-4, 11056-06-7 5360373
14
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
15
Sulfamethoxazole Approved Phase 4 723-46-6 5329
16
Nelfinavir Approved Phase 4 159989-64-7 64143
17
Methadone Approved Phase 4 76-99-3, 1095-90-5 4095
18
Lopinavir Approved Phase 4 192725-17-0 92727
19
Citalopram Approved Phase 4 59729-32-7, 59729-33-8 2771
20
Foscarnet Approved Phase 4 63585-09-1, 4428-95-9 3415
21
Valganciclovir Approved, Investigational Phase 4 175865-60-8 64147
22
Atovaquone Approved Phase 4 95233-18-4 74989
23
Acyclovir Approved Phase 4 59277-89-3 2022
24
Pyrimethamine Approved, Investigational, Vet_approved Phase 4 58-14-0, 19085-09-7 4993
25
Sulfadoxine Approved, Investigational Phase 4 2447-57-6 17134
26
Desipramine Approved, Investigational Phase 4 50-47-5 2995
27
Sulfadiazine Approved, Investigational, Vet_approved Phase 4 68-35-9 5215
28
Oxandrolone Approved, Investigational Phase 4 53-39-4 5878
29
Fosamprenavir Approved Phase 4 226700-79-4 131536
30
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 11128-99-7, 4474-91-3 172198
31
Spironolactone Approved Phase 4 1952-01-7, 52-01-7 5833
32
Velpatasvir Approved, Investigational Phase 4 1377049-84-7 77335690 67683363
33
Sofosbuvir Approved Phase 4 1190307-88-0 45375808
34
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4
35
Aminosalicylic acid Approved Phase 4 65-49-6 4649
36
Mesalazine Approved Phase 4 89-57-6 4075
37
Losartan Approved Phase 4 114798-26-4 3961
38
Carbamide peroxide Approved Phase 4 124-43-6
39
Mupirocin Approved, Investigational, Vet_approved Phase 4 12650-69-0 446596
40
Hydrocortisone succinate Approved Phase 4 2203-97-6 3643
41
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
42
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 3640 5754
43
Rivastigmine Approved, Investigational Phase 4 123441-03-2 77991
44
Lithium carbonate Approved Phase 4 554-13-2
45
Lactitol Approved, Investigational Phase 4 585-86-4 157355
46
Proguanil Approved Phase 4 500-92-5 4923 6178111
47
Racepinephrine Approved, Vet_approved Phase 4 51-43-4, 329-65-7 838 5816
48
Formaldehyde Approved, Vet_approved Phase 4 50-00-0 712
49
Bupropion Approved Phase 4 31677-93-7, 34841-39-9, 34911-55-2 444
50
Metamfetamine Approved, Illicit, Withdrawn Phase 4 537-46-2 10836

Interventional clinical trials:

(show top 50) (show all 4016)
# Name Status NCT ID Phase Drugs
1 Research on the Antiretroviral Therapy and Immune Reconstitution on Chinese HIV/AIDS Patients Unknown status NCT00872417 Phase 4 first line ARV (3TC+NVP+D4T or 3TC+NVP+AZT);second line ARV therapy (3TC+TDF+LPV/RTV)
2 The Evaluation of the Effectiveness of Bone-anchored Hearing Aids (Baha) in Patients With Conductive or Mixed Hearing Loss, or Unilateral Deafness Unknown status NCT01264510 Phase 4
3 Impact of HIV-1 and Aging on Mucosal Vaccine Responses Unknown status NCT03729778 Phase 4
4 Prospective Pilot Study of the Efficacy, Safety and Tolerability of Bictegravir-Based HIV ART Same-Day Treatment Evaluations (B-HASTE) Unknown status NCT04249037 Phase 4 bictegravir/emtricitabine/tenofovir alafenamide (BIC/F/TAF);Standard initiation of antiretroviral therapy (ART)
5 An Evaluation of Innovative Methods for Integrating Buprenorphine Opioid Treatment in HIV Primary Care Settings Unknown status NCT00124358 Phase 4 Buprenorphine
6 A Randomised, Multi-Centre, Open-Label Study in Well-Controlled Treatment-Experienced HIV-Infected Patients to Assess Compliance With a Once-Daily Regimen of Lamivudine, Efavirenz and Didanosine Versus Continuation of Current Anti-Retroviral Regimen Delivered at Least Twice Daily Unknown status NCT00214435 Phase 4 once daily minimum 3-drug regimen of anti-retroviral medications
7 A Phase 4, Single Arm, Open Label, Pilot Study of Maraviroc (Celsentri) in Combination With Raltegravir and Darunavir/Ritonavir for the Treatment of Triple Class Failure in Adult HIV-1 Infected Patients. Unknown status NCT01013987 Phase 4 maraviroc;Raltegravir;Darunavir/ritonavir
8 Evaluating the Feasibility and Acceptability of Implementing a PrEP Program in PR-CoNCRA (San Juan, Puerto Rico)- Part B Unknown status NCT03120494 Phase 4 Emtricitabine and Tenofovir
9 Evaluation of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Switch Followed by Sofosbuvir/Velpatasvir (SOF/VEL) Antiviral HCV Therapy Followed by Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) Simplification in HIV-HCV Co-Infected Subjects on Opioid Substitution Therapy - A Pilot Feasibility Study Unknown status NCT03549312 Phase 4 Genvoya;Epclusa;Biktarvy
10 Evaluation of the Pharmacokinetics of Antituberculosis Drugs and Tuberculosis Treatment Outcomes in HIV-tuberculosis Co-infected Ugandan Adults Unknown status NCT01782950 Phase 4 Rifampicin, Isoniazid, Ethambutol, Pyrazinamide
11 A Phase 4, Single-arm, Open-label Study to Evaluate the Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Once Daily Fixed-dose Combination (FDC) Regimen in Antiretroviral Treatment-experienced Human Immunodeficiency Virus Type 1 (HIV-1) Infected Subjects Not Currently Receiving Any Antiretroviral Therapy. Unknown status NCT04388904 Phase 4 Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (FDC)
12 Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Marginalized Populations Who Are Virologically Suppressed Unknown status NCT04132674 Phase 4 Bictegravir/emtricitabine/tenofovir alafenamide
13 Boosted PI VS. NNRTI Based Therapy as Initial Treatment for HIV-1 Infected Patients With Advanced Disease Unknown status NCT00162643 Phase 4 zidovudine+lamivudine+lopinavir/ritonavir;zidovudine + lamivudine + efavirenz
14 A Randomised Controlled Trial of a Strategy of Switching to Boosted PI Monotherapy Versus Continuing Combination ART for the Long-term Management of HIV-1 Infected Patients Who Have Achieved Sustained Virological Suppression on HAART Unknown status NCT01230580 Phase 4 Protease Inhibitor;Standard-of-care Antiretroviral therapy
15 A Prospective, Single Arm, Open-label 96 Week Observational Trial of the Tolerability, Adherence and Efficacy of a Dolutegravir/Abacavir/Lamivudine Single Tablet Regimen in HIV-1 Antibody Positive People Living With HIV With a History of Injection Drug Use Switching From Existing ART or Starting Treatment After Discontinuation of ART Unknown status NCT02659761 Phase 4 dolutegravir/abacavir/lamivudine
16 Topical Cyclosporine for the Treatment of Dry Eye in Patients Infected With the Human Immunodeficiency Virus Unknown status NCT00797030 Phase 4 cyclosporine and sodium carboximethycellulose;sodium carboximethycellulose
17 Effectiveness of Booster Vaccination With 1 or 2 Doses of Hepatitis A Vaccine Among HIV-infected Patients During an Ongoing Outbreak in Taiwan Unknown status NCT03855176 Phase 4 Vaqta Injectable Product
18 Multicenter, Open, Pilot Clinical Trial Aimed to Compare the Efficacy of RAL1200 QD vs DRV-cb 800-150 QD Both in Combination With TAF/FTC in Patients With HIV Infection and CD4 Count Under 200 Cells/microL Unknown status NCT03842488 Phase 4 Experimental: RAL QD;Active comparator: DRV/cb
19 Empiric Treatment for Suspected Acute HIV Infection in the Emergency Department Unknown status NCT03711253 Phase 4 Bictegravir 50mg+Tenofovir AF 25 mg+emtricitabine 200 mg
20 Efficacy of Intrathecal Administration of Liposomal Amphotericin B in Cryptococcal Meningitis Without Acquired Immune Deficiency Syndrome Unknown status NCT02686853 Phase 4 Liposomal amphotericin B
21 A Phase IV, Multicenter, Open and Randomized Study to Assess the Impact of the Change From Antiretroviral Treatment From Dual Therapy to Triple Therapy on Inflammation in Patients With Type 1 HIV Infection. InSTINCT Study Unknown status NCT04076423 Phase 4 Dual Therapy;Triple therapy
22 Integral Research of the Managing and Treatment of the Infection With Human Immunodeficiency (VIH) /Human Immunodeficiency Syndrome(SIDA) Co-infection With Latent Tuberculosis Infection. A Multidisciplinary and Interinstitucional Approach Unknown status NCT01875952 Phase 4 Isoniazid
23 Adjusting Antiretroviral Therapy Dosage Using Therapeutic Drug Monitoring Unknown status NCT00836212 Phase 4 Reducing dose of Lopinavir;Reducing dose of efavirenz
24 Immune Reconstitution in Severely Immunosuppressed Antiretroviral-naive HIV-1-Infected Patients (<100 CD4+ T Cells/μL) Taking Antiretroviral Regimens Based on Dolutegravir or Ritonavir-boosted Darunavir (the Advanz-4 Trial). Unknown status NCT02337322 Phase 4 Dolutegravir;Darunavir/r
25 Implication for Strategies of Long Term Control of Viral Replication in Patient With Primary HIV Infection (PHI) Treated With Multitarget Antiviral Therapy (MT-ART) Unknown status NCT04225325 Phase 4
26 Metformin Administration Effect Over Systemic Inflammation Serum Markers in HIV Positive Prediabetic Patients Unknown status NCT03774108 Phase 4 Metformin Hydrochloride 850 MG
27 A Randomized Non-Inferiority Trial to Compare the Efficacy of Switching From Protease-Inhibitor Based Second-Line Therapy to Bictegravir-Tenofovir Alafenamide-Emtricitabine in Virologically Suppressed Adults in Haiti Unknown status NCT04311957 Phase 4 Continuation of boosted PI;B/F/TAF
28 Pilot Single-Arm Clinical Trial to Evaluate the Efficacy, PK Interactions and Safety of Dolutegravir Plus 2 NRTIs in HIV-1-Infected Solid Organ Transplant Patients Unknown status NCT03360682 Phase 4 Lamivudine 300 MG;Abacavir 600 MG;Dolutegravir 50 mg;Tenofovir Disoproxil 245Mg Tablet;Emtricitabine 200 MG
29 Neurocognitive Function Improvement After Switching From Efavirenz to Rilpivirine in HIV-infected Adults: A Randomized Control Trial Unknown status NCT03567304 Phase 4 Rilpivirine 25 mg
30 Safety and Immune Response to Adjuvanted A(H1N1)v Influenza Vaccine in HIV-1 Infected and Immunosuppressed Adults Unknown status NCT01017172 Phase 4
31 Impact of Starting a Dolutegravir-based Regimen on HIV-1 Proviral DNA Reservoir Of Treatment Naïve and Experienced Patients Unknown status NCT02370979 Phase 4
32 Effect of Maraviroc (MCV) on the Immunological Recovery of HIV-1 Discordant Patients With CD4 Lymphocyte Counts Below 200 Cells/mm3 Unknown status NCT01235013 Phase 4 Maraviroc
33 A Randomized Comparison of Virco®TYPE HIV-1 Testing Versus Expert Interpretation of Genotypic Results for Control of HIV-1 Replication Unknown status NCT00840762 Phase 4
34 HIV Pre-Exposure Prophylaxis Priming of Immune Effectors Unknown status NCT02593409 Phase 4 TDF/FTC
35 An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of a Fixed-Dose Combination of Abacavir 600 mg/Lamivudine 300 mg Once-Daily in Combination With Atazanavir 300 mg + Ritonavir 100 mg Once-Daily in Antiretroviral-Naïve HIV-1 Infected Subjects With Continuing Evaluation of Abacavir/Lamivudine Plus Atazanavir 400 mg for Maintenance Over an Additional 48 Weeks Unknown status NCT00426296 Phase 4 atazanavir (Reyataz);ritonavir (Norvir)
36 A Phase IV, Open-Label, Randomized Study to Compare the Efficacy and Safety of Epivir/Ziagen/Zerit (3TC/ABC/d4T) Versus Epivir/Ziagen/Sustiva (3TC/ABC/EFV) Versus Epivir/Ziagen/Agenerase/Norvir (3TC/ABC/APV/RTV) for 96 Weeks in the Treatment of HIV-1 Infected Subjects Who Are Antiretroviral Therapy Naive Unknown status NCT00005017 Phase 4 Ritonavir;Abacavir sulfate;Amprenavir;Efavirenz;Lamivudine;Stavudine
37 A Randomized, Open-Label, Study of Nelfinavir or Efavirenz in HIV-1 Infected, Antiretroviral Naive Patients Unknown status NCT00005000 Phase 4 Nelfinavir mesylate;Efavirenz;Lamivudine;Keyhole-Limpet Hemocyanin;Stavudine;Zidovudine;Didanosine
38 A Phase IV Multicenter Study of the Efficacy and Safety of 48-Week Induction Treatment With TRIZIVIR (Abacavir 300 Mg/Lamivudine 150 Mg/Zidovudine 300 Mg Combination Tablet BID) With Efavirenz (600 Mg QD) Followed by 48-Week Randomized, Open-Label, Maintenance Treatment With TRIZIVIR With or Without Efavirenz in HIV-1 Infected Antiretroviral Therapy Naive Subjects Unknown status NCT00011895 Phase 4 Abacavir sulfate, Lamivudine and Zidovudine;Efavirenz
39 Effects of Mycophenolate Mofetil (MMF) on Surrogate Markers for Cardiovascular Disease in HIV-1 Infected Patients Unknown status NCT00247494 Phase 4 mycophenol mofetil (MMF, Cellcept®) 500 mg BID
40 An Open, Single-Arm, Multi-Center, Phase IV Pilot Study of Treatment of Antiretroviral Naive HIV-1 Infected Patients With Tenofovir Disoproxil Fumarate in Combination With Emtricitabine and Zidovudine Unknown status NCT00199121 Phase 4 Zidovudine (drug)
41 An Open Pilot Study to Evaluate the Efficacy and Safety, Tolerability of Raltegravir(RAL)in Treatment-experienced HIV-1 Infected Adult Chinese Patients Unknown status NCT01201239 Phase 4 raltegravir
42 Statin Modulation of Monocyte/Macrophage Activation for HAND Treatment Completed NCT01600170 Phase 4 Atorvastatin (generic Lipitor);placebo
43 A Phase IV Study of Antiretroviral Therapy for HIV Infected Adults Presenting With Acute Opportunistic Infections: Immediate Versus Deferred Initiation of Antiretroviral Therapy Completed NCT00055120 Phase 4 Emtricitabine/tenofovir disoproxil fumarate;Lopinavir/ritonavir;Stavudine
44 Pilot Study to Evaluate Effects of Atorvastatin on Monocyte Activation in HAART-treated HIV Infected Individuals Completed NCT01263938 Phase 4 Atorvastatin
45 SSRI Effects on Depression and Immunity in HIV/AIDS Completed NCT02620150 Phase 4 Escitalopram
46 A Phase 4 Open Label Study to Assess the Safety and Effects of Crofelemer on the Gut Microbiome in Healthy Volunteers and in People Living With HIV/AIDS (PLWHA) With Non-Infectious Diarrhea Completed NCT04192487 Phase 4 Crofelemer delayed-release tablets 125mg
47 Routine Use of Antiretroviral Therapy to Prevent Mother-to-Child HIV Transmission in the Kafue District of Zambia (Impact of HAART to Prevent Pediatric AIDS in Rural Zambia). Completed NCT00753324 Phase 4 Routine three-drug antiretroviral prophylaxis
48 A Randomized Comparison of Protease Inhibitor-based Versus Non-nucleoside Reverse Transcriptase Inhibitor-based Antiretroviral Therapy for Initial Treatment of Individuals With AIDS-related Kaposi's Sarcoma in Sub-Saharan Africa Completed NCT00444379 Phase 4 Lopinavir/ritonavir plus Emtricitabine/Tenofovir versus Efavirenz plus Emtricitabine/Tenofovir
49 Extracts of Plants Eclipta Prostrata, Dioscorea Cirrhosa, Phyllanthus Urinaria, Adenosma Glutinosum, Impatiens Balsamina and Ascorbic Acid Use for in Protecting and Increasing CD4+ T Lymphocytes; B Lymphocytes Level in HIV/AIDS Patients. Completed NCT04770701 Phase 4 Ahah Drug
50 A Strategy Study of Immediate Versus Deferred Initiation of Antiretroviral Therapy for AIDS Disease-Free Survival in HIV-Infected Persons Treated for Tuberculosis With CD4 Less Than 250 Cells/mm^3 Completed NCT00108862 Phase 4

Search NIH Clinical Center for Human Immunodeficiency Virus Type 1

Inferred drug relations via UMLS 71 / NDF-RT 50 :


abacavir
abacavir sulfate
Amprenavir
Delavirdine
Delavirdine Mesylate
Didanosine
efavirenz
enfuvirtide
Immunoglobulins, Intravenous
Indinavir
Indinavir Sulfate
Lamivudine
lopinavir
Nelfinavir
Nelfinavir Mesylate
Nevirapine
Ritonavir
Saquinavir
saquinavir mesylate
Stavudine
Tenofovir
tenofovir alafenamide fumarate
Tenofovir disoproxil fumarate
Zalcitabine
Zidovudine

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Human Immunodeficiency Virus Type 1 cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Human Immunodeficiency Virus Type 1:
AGS-004, electroporated mature dendritic cells for HIV
Embryonic/Adult Cultured Cells Related to Human Immunodeficiency Virus Type 1:
Maturated and electroporated dendritic cells PMIDs: 20636001

Genetic Tests for Human Immunodeficiency Virus Type 1

Anatomical Context for Human Immunodeficiency Virus Type 1

Organs/tissues related to Human Immunodeficiency Virus Type 1:

MalaCards : T Cells, Brain, Lymph Node, Bone Marrow, Bone, Liver, Breast

Publications for Human Immunodeficiency Virus Type 1

Articles related to Human Immunodeficiency Virus Type 1:

(show top 50) (show all 70054)
# Title Authors PMID Year
1
Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. 53 62 57 5
12134147 2002
2
Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. ALIVE Study, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC) 53 62 57 5
9430590 1998
3
Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study. 53 62 57 5
9252328 1997
4
HLA-C cell surface expression and control of HIV/AIDS correlate with a variant upstream of HLA-C. 62 57 5
19935663 2009
5
Association of DC-SIGN promoter polymorphism with increased risk for parenteral, but not mucosal, acquisition of human immunodeficiency virus type 1 infection. 62 57 5
15564514 2004
6
Genetic restriction of HIV-1 pathogenesis to AIDS by promoter alleles of IL10. 62 57 5
11121048 2000
7
A common polymorphism in TLR3 confers natural resistance to HIV-1 infection. 57 5
22174453 2012
8
MCP-1-MCP-3-Eotaxin gene cluster influences HIV-1 transmission. 57 5
14571188 2003
9
Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. 57 5
8751444 1996
10
Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. 57 5
8756719 1996
11
HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. 53 62 57
17243065 2007
12
Polymorphisms in the interleukin-4 receptor alpha chain gene influence susceptibility to HIV-1 infection and its progression to AIDS. 53 62 57
16189667 2005
13
Genetic acceleration of AIDS progression by a promoter variant of CCR5. 53 62 57
9836644 1998
14
CCR5 promoter polymorphism and HIV-1 disease progression. Multicenter AIDS Cohort Study (MACS). 53 62 5
9742978 1998
15
Mutational analysis of the CCR5 and CXCR4 genes (HIV-1 co-receptors) in resistance to HIV-1 infection and AIDS development among intravenous drug users. 53 62 5
9600249 1998
16
Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. 53 62 57
8791590 1996
17
SERINC3 and SERINC5 restrict HIV-1 infectivity and are counteracted by Nef. 62 57
26416733 2015
18
Vif hijacks CBF-β to degrade APOBEC3G and promote HIV-1 infection. 62 57
22190037 2011
19
The cytosolic exonuclease TREX1 inhibits the innate immune response to human immunodeficiency virus type 1. 62 57
20871604 2010
20
Divergent TLR7 and TLR9 signaling and type I interferon production distinguish pathogenic and nonpathogenic AIDS virus infections. 62 57
18806803 2008
21
Duffy antigen receptor for chemokines mediates trans-infection of HIV-1 from red blood cells to target cells and affects HIV-AIDS susceptibility. 62 57
18621010 2008
22
Apolipoprotein (apo) E4 enhances HIV-1 cell entry in vitro, and the APOE epsilon4/epsilon4 genotype accelerates HIV disease progression. 62 57
18562290 2008
23
Cellular microRNAs contribute to HIV-1 latency in resting primary CD4+ T lymphocytes. 62 57
17906637 2007
24
A whole-genome association study of major determinants for host control of HIV-1. 62 57
17641165 2007
25
Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211. 62 57
17570119 2007
26
Pharmacogenetics of antiretroviral drugs for the treatment of HIV-infected patients: an update. 62 57
17045554 2007
27
A haplotype of the human CXCR1 gene protective against rapid disease progression in HIV-1+ patients. 53 57
17360650 2007
28
Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1. 62 57
17306567 2007
29
Structural definition of a conserved neutralization epitope on HIV-1 gp120. 62 57
17301785 2007
30
CCR5 deficiency increases risk of symptomatic West Nile virus infection. 62 5
16418398 2006
31
AIDS restriction HLA allotypes target distinct intervals of HIV-1 pathogenesis. 62 57
16288280 2005
32
The case for selection at CCR5-Delta32. 53 5
16248677 2005
33
The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. 62 57
15637236 2005
34
Influence of host genetic variation on susceptibility to HIV type 1 infection. 62 57
15630678 2005
35
Human genes that limit AIDS. 62 57
15167933 2004
36
Modulating influence on HIV/AIDS by interacting RANTES gene variants. 62 57
12114533 2002
37
The coreceptor mutation CCR5Delta32 influences the dynamics of HIV epidemics and is selected for by HIV. 62 5
11517319 2001
38
Chemokine receptor polymorphism in transplantation immunology: no longer just important in AIDS. 62 5
11403804 2001
39
A homologous naturally occurring mutation in Duffy and CCR5 leading to reduced receptor expression. 53 5
11369664 2001
40
Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS. 62 57
11386265 2001
41
Rapid progression to AIDS in HIV+ individuals with a structural variant of the chemokine receptor CX3CR1. 62 57
10731151 2000
42
HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. 62 57
10073943 1999
43
Dating the origin of the CCR5-Delta32 AIDS-resistance allele by the coalescence of haplotypes. 62 5
9585595 1998
44
Inherited resistance to HIV-1 conferred by an inactivating mutation in CC chemokine receptor 5: studies in populations with contrasting clinical phenotypes, defined racial background, and quantified risk. 53 5
9132277 1997
45
Elevated HLA-A expression impairs HIV control through inhibition of NKG2A-expressing cells. 57
29302013 2018
46
HIV-1 Nef promotes infection by excluding SERINC5 from virion incorporation. 57
26416734 2015
47
HIV Blocks Interferon Induction in Human Dendritic Cells and Macrophages by Dysregulation of TBK1. 57
25855743 2015
48
PQBP1 Is a Proximal Sensor of the cGAS-Dependent Innate Response to HIV-1. 57
26046437 2015
49
TOE1 is an inhibitor of HIV-1 replication with cell-penetrating capability. 57
26056259 2015
50
Kruppel-like factor 2 modulates CCR5 expression and susceptibility to HIV-1 infection. 57
22988032 2012

Variations for Human Immunodeficiency Virus Type 1

ClinVar genetic disease variations for Human Immunodeficiency Virus Type 1:

5 (show all 18)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 CCR5, CCR5AS NM_001394783.1(CCR5):c.554_585del (p.Ser185fs) DEL Protective
8184 rs333 GRCh37: 3:46414944-46414975
GRCh38: 3:46373453-46373484
2 CCR5, CCR5AS NM_001394783.1(CCR5):c.303T>A (p.Cys101Ter) SNV Protective
8188 rs1800560 GRCh37: 3:46414696-46414696
GRCh38: 3:46373205-46373205
3 CCR5, CCR5AS NM_001394783.1(CCR5):c.180G>T (p.Arg60Ser) SNV Protective
8191 rs1800940 GRCh37: 3:46414573-46414573
GRCh38: 3:46373082-46373082
4 CCR2 NM_001123396.4(CCR2):c.190G>A (p.Val64Ile) SNV Protective
8267 rs1799864 GRCh37: 3:46399208-46399208
GRCh38: 3:46357717-46357717
5 CCL11 NG_012212.1:g.3760= SNV Protective
8367 rs4795895 GRCh37: 17:32611446-32611446
GRCh38: 17:34284427-34284427
6 CXCL12 NM_199168.4(CXCL12):c.*531G>A SNV Protective
8762 rs387906400 GRCh37: 10:44873550-44873550
GRCh38: 10:44378102-44378102
7 CCL2 NG_012123.1:g.2936= SNV Protective
14205 GRCh37: 17:32580231-32580231
GRCh38: 17:34253212-34253212
8 CCL2 NM_002982.4(CCL2):c.77-109= SNV Protective
14206 GRCh37: 17:32583132-32583132
GRCh38: 17:34256113-34256113
9 TLR3 NM_003265.3(TLR3):c.1234C>T (p.Leu412Phe) SNV Protective
41472 rs3775291 GRCh37: 4:187004074-187004074
GRCh38: 4:186082920-186082920
10 CCR5, CCR5AS NM_000579.4(CCR5):c.-301+246A>G SNV Protective
8189 rs1799987 GRCh37: 3:46411935-46411935
GRCh38: 3:46370444-46370444
11 KIR3DL1 KIR3DS, KIR3DS +/- HLA-B Bw4-80ILE VAR Pathogenic
5288 GRCh37:
GRCh38:
12 CD209, LOC117307477 NG_012167.1:g.4732T>C SNV Risk Factor
5408 GRCh37: 19:7812733-7812733
GRCh38: 19:7747847-7747847
13 IL10, IL19 NM_153758.5(IL19):c.-149+1984T>G SNV Risk Factor
16873 rs1800872 GRCh37: 1:206946407-206946407
GRCh38: 1:206773062-206773062
14 HLA-C NC_000006.12:g.31306603T>C SNV Risk Factor
14907 rs9264942 GRCh37: 6:31274380-31274380
GRCh38: 6:31306603-31306603
15 IL4R NM_000418.4(IL4R):c.1774G>T (p.Val592Leu) SNV Uncertain Significance
827982 rs138392496 GRCh37: 16:27374447-27374447
GRCh38: 16:27363126-27363126
16 CXCR1 NM_000634.3(CXCR1):c.3G>A (p.Met1Ile) SNV Uncertain Significance
992524 rs55808468 GRCh37: 2:219029932-219029932
GRCh38: 2:218165209-218165209
17 IL4R NM_000418.4(IL4R):c.1160C>T (p.Ser387Leu) SNV Uncertain Significance
626118 rs6413500 GRCh37: 16:27373833-27373833
GRCh38: 16:27362512-27362512
18 CX3CR1 NM_001171174.1(CX3CR1):c.10C>G (p.Pro4Ala) SNV Uncertain Significance
992523 rs147724093 GRCh37: 3:39323177-39323177
GRCh38: 3:39281686-39281686

Copy number variations for Human Immunodeficiency Virus Type 1 from CNVD:

6 (show all 23)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 13736 1 1 247249719 Copy number HIV/AIDS
2 74031 13 1 114142980 Copy number HIV/AIDS
3 107129 17 1225928 31649829 Copy number CCL3L3 HIV/AIDS
4 107135 17 1225928 31649843 Copy number CCL3L1 HIV/AIDS
5 107136 17 1225928 31649843 Copy number CCL3L1 HIV/AIDS
6 107137 17 1225928 31649843 Copy number CCL3L1 HIV/AIDS
7 107145 17 1225928 31649843 Segmental duplications CCL3L1 HIV/AIDS
8 107159 17 1242109 31665953 Copy number CCL4L2 HIV/AIDS
9 110228 17 31562580 31665959 Copy number CCL4L1 HIV/AIDS
10 110279 17 31800000 38100000 Copy number CCL3L1 HIV/AIDS
11 110285 17 31800000 38100000 Copy number CCL4L1 HIV/AIDS
12 110286 17 31800000 38100000 Copy number CCL4L1 HIV/AIDS
13 110848 17 34522267 34625730 Copy number CCL3L1 HIV/AIDS
14 111275 17 35400000 35600000 Copy number CCL3L1 HIV/AIDS
15 112166 17 38100000 38400000 Copy number CCL3L1 HIV/AIDS
16 112167 17 38100000 38400000 Copy number CCL3L1 HIV/AIDS
17 112170 17 38100000 38400000 Loss CCL3L1 HIV/AIDS
18 179925 4 1 191273063 Copy number HIV/AIDS
19 209403 6 2614953 31491069 Copy number MICA HIV/AIDS
20 211349 6 32593131 32665540 Copy number HLA-DRB5 HIV/AIDS
21 212276 6 3674895 32665540 Copy number HLA-DRB1 HIV/AIDS
22 212425 6 3795995 32719407 Copy number HLA-DQA1 HIV/AIDS
23 212441 6 3813334 32742444 Copy number HLA-DQB1 HIV/AIDS

Expression for Human Immunodeficiency Virus Type 1

LifeMap Discovery
Genes differentially expressed in tissues of Human Immunodeficiency Virus Type 1 patients vs. healthy controls: 35 (show all 32)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 RBM25 RNA binding motif protein 25 Blood - 4.35 0.000
2 UBXN4 UBX domain protein 4 Blood - 4.25 0.000
3 LUC7L3 LUC7 like 3 pre-mRNA splicing factor Blood - 4.07 0.000
4 DKC1 dyskerin pseudouridine synthase 1 Blood - 4.00 0.000
5 XIST X inactive specific transcript Lymph - 3.89 0.000
6 SYNCRIP synaptotagmin binding cytoplasmic RNA interacting protein Blood - 3.79 0.000
7 AP3D1 adaptor related protein complex 3 subunit delta 1 Blood - 3.77 0.000
8 SRRM2 serine/arginine repetitive matrix 2 Blood - 3.74 0.000
9 SON SON DNA and RNA binding protein Blood - 3.73 0.000
10 PTPRC protein tyrosine phosphatase receptor type C Blood - 3.67 0.000
11 NKTR natural killer cell triggering receptor Blood - 3.57 0.000
12 ESF1 ESF1 nucleolar pre-rRNA processing protein homolog Blood - 3.53 0.000
13 RBL2 RB transcriptional corepressor like 2 Blood - 3.49 0.000
14 ADAM28 ADAM metallopeptidase domain 28 Blood - 3.48 0.000
15 PNISR PNN interacting serine and arginine rich protein Blood - 3.44 0.000
16 HSP90AA1 heat shock protein 90 alpha family class A member 1 Blood - 3.38 0.000
17 SCAF11 SR-related CTD associated factor 11 Blood - 3.36 0.000
18 NBPF10 NBPF member 10 Blood - 3.35 0.000
19 PRRC2C proline rich coiled-coil 2C Blood - 3.32 0.000
20 LRRN3 leucine rich repeat neuronal 3 Blood - 3.28 0.000
21 PPIG peptidylprolyl isomerase G Blood - 3.27 0.000
22 IFI27 interferon alpha inducible protein 27 Blood + 3.25 0.000
23 TRIM23 tripartite motif containing 23 Blood - 3.23 0.000
24 ANKRD12 ankyrin repeat domain 12 Blood - 3.22 0.000
25 EIF1AY eukaryotic translation initiation factor 1A Y-linked Lymph + 3.18 0.000
26 CHD4 chromodomain helicase DNA binding protein 4 Blood - 3.12 0.000
27 TNFAIP2 TNF alpha induced protein 2 Blood - 3.11 0.000
28 PTMA prothymosin alpha Blood - 3.10 0.000
29 USO1 USO1 vesicle transport factor Blood - 3.09 0.000
30 ATRX ATRX chromatin remodeler Blood - 3.06 0.000
31 PRMT2 protein arginine methyltransferase 2 Blood - 3.04 0.000
32 TBL1X transducin beta like 1 X-linked Blood - 3.03 0.000
Search GEO for disease gene expression data for Human Immunodeficiency Virus Type 1.

Pathways for Human Immunodeficiency Virus Type 1

Pathways related to Human Immunodeficiency Virus Type 1 according to GeneCards Suite gene sharing:

(show all 48)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.91 CCL11 CCL2 CCL3 CCL3L1 CCL5 CCR2
2
Show member pathways
13.81 IL4R IL10 CXCR4 CXCR1 CXCL12 CX3CR1
3 13.78 CCL11 CCL2 CCL3 CCL3L1 CCL5 CCNT1
4
Show member pathways
13.59 CCL11 CCL2 CCL3 CCL3L1 CCL5 CCR2
5
Show member pathways
13.55 IL4R IL10 IFNG CXCR4 CXCL12 CCL5
6
Show member pathways
13.52 IL4R IL10 IFNG CXCR4 CXCR1 CXCL12
7
Show member pathways
13.42 CXCR4 CXCR1 CXCL12 CCR5 CCR2 CCL5
8
Show member pathways
13.36 CXCR4 CXCR1 CXCL12 CX3CR1 CCR5 CCR2
9
Show member pathways
13.28 IL4R IL10 IFNG HLA-C CCR5 CCR2
10
Show member pathways
13.2 IL4R IL10 CXCR4 CXCR1 CXCL12 CX3CR1
11
Show member pathways
13.15 TLR3 IL4R IL10 CXCR4 CXCR1 CXCL12
12
Show member pathways
12.73 CCL11 CCL2 CCL3 CCL3L1 CCL5 CCR2
13
Show member pathways
12.67 IL4R IL10 IFNG HLA-C CXCR4 CXCL12
14 12.52 CCL2 CCL5 CCR2 CXCL12 CXCR4 IFNG
15
Show member pathways
12.45 CCR2 CCR5 CXCR4 IL4R
16
Show member pathways
12.18 IL4R CXCR4 CCR5 CCR2
17 12.01 IL10 IFNG CX3CR1 CD209
18 11.97 IL4R IL10 CCL2 CCL11
19
Show member pathways
11.92 IFNG CCR5 CCL3
20 11.9 IL10 IFNG HLA-C CXCL12
21 11.89 IL10 CXCR4 CCR5 CCR2 CCL3 CCL2
22 11.88 CXCR1 CCR5 CCR2
23
Show member pathways
11.87 TLR3 IL10 IFNG
24
Show member pathways
11.83 TLR3 IL4R IFNG
25 11.82 CCR5 CXCR4 IFNG IL10 TLR3
26 11.8 IL10 IFNG CX3CR1 CD209
27 11.77 IL10 IFNG CCL3
28 11.77 CXCL12 CXCR4 IFNG IL10
29 11.73 CXCR4 CXCL12 CCL2
30 11.73 CCR2 CCL5 CCL3 CCL2 CCL11
31 11.69 IL10 IFNG CCL2
32 11.63 IL4R IL10 CCL11
33
Show member pathways
11.62 IL4R IL10 IFNG
34 11.61 IL10 CCL5 CCL3 CCL2
35 11.56 IL4R IL10 IFNG CCL11
36 11.52 IFNG CCR2 CCL2
37 11.52 IL4R CCL5 CCL2
38
Show member pathways
11.47 CXCR4 CXCR1 CXCL12 CX3CR1 CCR5 CCR2
39
Show member pathways
11.39 IL10 IFNG CCL3
40 11.34 CX3CR1 CCR2 CCL2
41 11.32 CXCR4 CXCL12 CCL5
42 11.3 IFNG CCL5 CCL3 CCL2
43 11.27 CCR2 CCL3 CCL2
44 11.17 IL10 CCR5 CCR2 CCL5 CCL3L1 CCL3
45 11.06 IL10 CXCL12 CCL5 CCL3L1 CCL3 CCL2
46 10.99 CCR2 CCR5 IFNG IL4R
47 10.9 CCL3 CCL2
48 10.68 CCL3 CCL2

GO Terms for Human Immunodeficiency Virus Type 1

Cellular components related to Human Immunodeficiency Virus Type 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 10.13 TLR3 IL4R IL10 IFNG CXCL12 CCL5
2 plasma membrane GO:0005887 9.96 CCR2 CCR5 CX3CR1 HLA-C IL4R KIR3DL1
3 plasma membrane GO:0005886 9.96 CCR2 CCR5 CX3CR1 HLA-C IL4R KIR3DL1
4 external side of plasma membrane GO:0009897 9.53 IL4R CXCR4 CXCR1 CXCL12 CX3CR1 CD209

Biological processes related to Human Immunodeficiency Virus Type 1 according to GeneCards Suite gene sharing:

(show all 42)
# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor signaling pathway GO:0007186 10.59 CCL11 CCL2 CCL3 CCL3L1 CCL5 CCR2
2 signal transduction GO:0007165 10.48 TLR3 IL4R IL10 IFNG CXCR4 CXCR1
3 inflammatory response GO:0006954 10.36 CCL11 CCL2 CCL3 CCL3L1 CCL5 CCR2
4 positive regulation of cell migration GO:0030335 10.35 CXCR4 CXCL12 CCL5 CCL3 CCL11
5 positive regulation of ERK1 and ERK2 cascade GO:0070374 10.33 CCL5 CCL3L1 CCL3 CCL2 CCL11
6 positive regulation of GTPase activity GO:0043547 10.33 CCL11 CCL2 CCL3 CCL3L1 CCL5
7 positive regulation of cytosolic calcium ion concentration GO:0007204 10.32 CXCR4 CXCR1 CX3CR1 CCR5 CCR2
8 cellular response to tumor necrosis factor GO:0071356 10.29 CCL11 CCL2 CCL3 CCL3L1 CCL5
9 cellular response to type II interferon GO:0071346 10.29 TLR3 CCL5 CCL3L1 CCL3 CCL2 CCL11
10 cellular calcium ion homeostasis GO:0006874 10.28 CXCL12 CCR2 CCL5 CCL3 CCL11
11 cellular response to interleukin-1 GO:0071347 10.27 CCL11 CCL2 CCL3 CCL3L1 CCL5
12 calcium-mediated signaling GO:0019722 10.27 CCL3 CCR2 CCR5 CX3CR1 CXCR1 CXCR4
13 response to virus GO:0009615 10.26 CCL11 CCL5 CXCL12 CXCR4 IFNG TLR3
14 MAPK cascade GO:0000165 10.25 TLR3 CCR5 CCL5 CCL3 CCL2
15 positive regulation of inflammatory response GO:0050729 10.24 CCL3 CCR2 IFNG TLR3
16 positive regulation of tumor necrosis factor production GO:0032760 10.24 TLR3 IFNG CCR2 CCL3
17 neutrophil chemotaxis GO:0030593 10.23 CCL11 CCL2 CCL3 CCL3L1 CCL5 CXCR1
18 cellular response to organic cyclic compound GO:0071407 10.16 CCL5 CCL3 CCL2
19 protein kinase B signaling GO:0043491 10.16 CCL5 CCL3 CCL2
20 cellular defense response GO:0006968 10.16 CX3CR1 CCR5 CCR2
21 positive regulation of monocyte chemotaxis GO:0090026 10.16 CXCL12 CX3CR1 CCR2 CCL5
22 positive regulation of chemokine production GO:0032722 10.15 TLR3 IL4R IFNG
23 monocyte chemotaxis GO:0002548 10.15 CCR2 CCL5 CCL3L1 CCL3 CCL2 CCL11
24 receptor signaling pathway via JAK-STAT GO:0007259 10.14 IFNG CCR2 CCL2
25 eosinophil chemotaxis GO:0048245 10.14 CCL5 CCL3 CCL2 CCL11
26 lipopolysaccharide-mediated signaling pathway GO:0031663 10.13 CCL2 CCL3 CCL5
27 lymphocyte chemotaxis GO:0048247 10.13 CCL5 CCL3L1 CCL3 CCL2 CCL11
28 cell chemotaxis GO:0060326 10.13 CCL2 CCL3 CCL5 CCR2 CCR5 CX3CR1
29 chemotaxis GO:0006935 10.13 CCL3L1 CCL3 CCL2 CCL11 CCL5 CCR2
30 macrophage chemotaxis GO:0048246 10.09 CCL2 CCL3 CCL5
31 positive regulation of calcium ion import GO:0090280 10.08 CCL2 CCL3 CXCL12
32 immune response GO:0006955 10.07 TLR3 KIR3DL1 IL4R IL10 IFNG HLA-C
33 positive regulation of NMDA glutamate receptor activity GO:1904783 10.05 IFNG CCR2 CCL2
34 positive regulation of neurogenesis GO:0050769 10.04 IFNG CXCR4 CX3CR1
35 dendritic cell chemotaxis GO:0002407 10.02 CXCR4 CXCR1 CCR5 CCR2 CCL5
36 release of sequestered calcium ion into cytosol by sarcoplasmic reticulum GO:0014808 9.99 CCR5 CCL3
37 astrocyte cell migration GO:0043615 9.98 CCL2 CCL3
38 positive regulation of microglial cell migration GO:1904141 9.97 CCL3 CX3CR1
39 positive regulation of natural killer cell chemotaxis GO:2000503 9.96 CCL5 CCL3
40 telencephalon cell migration GO:0022029 9.96 CXCR4 CXCL12
41 response to ultrasound GO:1990478 9.92 CXCR4 CXCL12
42 chemokine-mediated signaling pathway GO:0070098 9.64 CCL11 CCL2 CCL3 CCL3L1 CCL5 CCR2

Molecular functions related to Human Immunodeficiency Virus Type 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 CCR chemokine receptor binding GO:0048020 10.07 CCL5 CCL3L1 CCL3 CCL2 CCL11
2 cytokine activity GO:0005125 10.02 IL10 IFNG CXCL12 CCL5 CCL3L1 CCL3
3 C-C chemokine binding GO:0019957 9.96 CCR2 CCR5 CX3CR1 CXCR1 CXCR4
4 C-C chemokine receptor activity GO:0016493 9.85 CXCR4 CXCR1 CX3CR1 CCR5 CCR2
5 CCR5 chemokine receptor binding GO:0031730 9.76 CCL5 CCL3
6 CCR2 chemokine receptor binding GO:0031727 9.73 CCR2 CCL2
7 CCR1 chemokine receptor binding GO:0031726 9.71 CCL5 CCL3
8 C-X-C chemokine receptor activity GO:0016494 9.65 CXCR4 CXCR1
9 chemokine receptor activity GO:0004950 9.61 CXCR4 CXCR1 CX3CR1 CCR5 CCR2
10 chemokine activity GO:0008009 9.4 CXCL12 CCL5 CCL3L1 CCL3 CCL2 CCL11

Sources for Human Immunodeficiency Virus Type 1

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....